Navigation Links
Pinpointing a culprit molecule in Alzheimer's disease

One puzzle in Alzheimer's disease (AD) research is why mice engineered to have the abnormal protein underlying the disease in humans show little pathology of the disease. Specifically, such mice are genetically altered to overproduce mutant human amyloid precursor protein (APP). It is this protein that, when clipped by enzymes, produces the amyloid beta (Ab) peptide that clusters into the amyloid plaque that clogs the brain and kills brain cells.

The clipping of APP produces two types of amyloid beta peptide--one 40 amino acid units long (Ab40) and one 42 units long (Ab42). Circumstantial evidence has suggested that Ab42 is the "stickier" of the two forms, and underlies the pathology of the disease.

Now, researchers led by Eileen McGowan and Todd Golde of the Mayo Clinic College of Medicine report in the July 21, 2005, issue of Neuron definitive proof that Ab42 is, indeed, the culprit molecule. In their experiments, they created transgenic mice that overproduced either Ab40 or Ab42 in the absence of overproduction of APP. Thus, they could precisely study the role of each of these molecules in AD pathology.

Their studies of the mice revealed that the Ab40 mice showed little amyloid disease pathology in the animals' brains, while the Ab42 mice showed extensive accumulation of amyloid plaque and resulting neural damage. What's more, when the researchers crossed the Ab42 mice with those producing mutant APP, they saw a massive increase in amyloid deposition that was more than the additive effect of the two mutations.

The researchers pointed out that test tube studies have shown that Ab42 aggregates more readily. "Thus, the simplest explanation for the complete lack of pathology in the [Ab40] mice would be the relative inability of Ab40 to initiate nucleation events capable of promoting amyloid deposition," they wrote.

One question the new transgenic mice might help address, wrote the researchers, is whether Ab peptide does damage i
'"/>

Source:Cell Press


Page: 1 2

Related biology news :

1. Pinpointing the cause of a neurodegenerative disorder
2. Chemists create Superbowl molecule; May lead to better health
3. Key molecule in plant photo-protection identified
4. Inflammatory molecules released by pollen trigger allergies
5. Researchers discover molecule that causes secondary stroke
6. Yale researchers identify molecule for detecting parasitic infection in humans
7. Scientists identify molecule that regulates well-known tumor suppressor
8. Medical molecules designed to respond to visible light that can penetrate tissue
9. Researchers find promising cancer-fighting power of synthetic cell-signaling molecule
10. Chemists synthesize molecule that helps body battle cancers, malaria
11. DNA constraints control structure of attached macromolecules

Post Your Comments:
(Date:11/9/2009)... inspired a 3.2m, three-year research project that...ecurity, energy and the environment. The Universit...inetiQ have just signed a collaborative contract t... physical sciences research. , Over the next th... of Exeter and QinetiQ will work together to devel...
(Date:11/9/2009)...eaders from around the world will gather in Boston...r Targets and Cancer Therapeutics International Co...ation on important cancer therapies in development...t effectively we need a greater understanding of t...l," said Lewis Cantley, Ph.D., director of the can...
(Date:11/8/2009)...S WITH INTELLECTUAL DISABILITIES: AN OPPORTUNITY F...y involving adults with intellectual disabilities ...lth knowledge after taking a semi-weekly class for...ly accepted term for mental retardation, have slig...and preventable chronic diseases compared to the g...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 2Indiana U. at APHA: Studies about health education for people with ID, stability balls at work 3Nevada Drug Card and Las Vegas Chamber Offer Rx Assistance 52973 1Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 1Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 2Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 3Report Shows New York City Companies Playing Key Role In Development of New Medicines for Wide Range of Diseases 52970 4New drug for children with high risk leukemia 52965 1New drug for children with high risk leukemia 52965 2
... of a sustainable biofuels industry in Tennessee h... of Energy has announced that Mascoma Corporation,...cipients of a $26 million grant for the developmen...s for demonstrating the production of cellulosic e... operations. The facility is to be constructed at ...
..., including malaria, dengue fever, and avian influ...l factors and, more recently, to climate change. R...e animals that carry and ultimately transmit these...occurs, these diseases may be introduced into area...standing the interactions that occur among climate...
...nse of Arctic sea ice is increasingly vulnerable t...dy, by scientists at the National Center for Atmos...ty (CSU), finds that unusually sunny weather contr... while similar weather conditions in past summers ...he study, which draws on observations from instrum...
Other Biology News:Mascoma and UT join in $26M DOE grant 2Mascoma and UT join in $26M DOE grant 3Scientists to explore global change-public health connection 2Arctic ice more vulnerable to sunny weather, new study shows 2Arctic ice more vulnerable to sunny weather, new study shows 3
(Date:11/5/2009)...ORDOVA, Calif., Nov. 5 T...plier of innovative products for processing and st... the first quarter of fiscal 2010. ,, For the q...ted revenues of $5.2 million, a 15 percent increas...er a year ago. The Company said the key contributo...
(Date:11/5/2009)...eb., Nov. 5 Transgenomic...financial results for the quarter ended September ...ented in the tables that follow. ,, Third Quar... $366,000 or $0.01 per share for the third quarter...$0.01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)...E, Calif., Nov. 5 Cephei...ives will be speaking at the following investor co...a webcast. , , Credit Suisse Healt...rsday, 12 November, 2009 at 10 a.m. Mountain Time,..., London, England, Tuesday, 1 Dece...
(Date:11/5/2009)...O, CA, November 5, 2009 ...on using proprietary taste receptor-based technolo...food, beverage, and ingredient supply industries, ...ancial results for the third quarter ended Septemb...hird quarter of 2009, compared to $4.0 million for...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7Cepheid to Webcast Upcoming Financial Presentations 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...RDAM, The Netherlands, February 11, Agendia, a wor...nounced the appointment of Alan B. Carter as the c...elopment. , "As we continue to grow as a globa...primary aims," commented Dr. Bernhard Sixt, Ph.D.,...sive business development expertise will,strengthe...
... (Pink Sheets: MNCN), a global health company that...ce positive, long term benefit to the agricultural... executed its definitive agreement to acquire Modu...ice of $500,000 in the form of Convertible Preferr...will allow Mach One to bring in house the engineer...
...A team of Los Alamos researchers led by Victor Kli...oton creates multiple electronsis a real phenomeno...bservation born of extraneous effects that mimic c...a recent issue of Accounts of Chemical Research ,...more than one unit of energy per photon. , Questi...
Other Biology Technology:Agendia Appoints VP of Business Development 2Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm 2Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3
HV Mini 5 (230V / 50Hz) from Thermo Scientific
Immulon 1 B 1x12 Strip from Thermo Scientific
Peptides from Thermo Scientific
RapidStak 2 (requires 4 staks, not included) from Thermo Scientific
Biology Products: